How to buy Gossamer Bio stock

Gossamer Bio, Inc is a biotechnology business based in the US. Gossamer Bio shares (GOSS) are listed on the NASDAQ and all prices are listed in US Dollars. Gossamer Bio employs 195 staff and has a market cap (total outstanding shares value) of 0.00.

Gossamer Bio share price

Use our graph to track the performance of GOSS stocks over time.

Gossamer Bio shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$7.92 - $16.79
50-day moving average	$9.12
200-day moving average	$9.67
Wall St. target price	$21.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.95

Buy Gossamer Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Gossamer Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Gossamer Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gossamer Bio financials

Gross profit TTM	$0
Return on assets TTM	-27.25%
Return on equity TTM	-72.3%
Profit margin	0%
Book value	$4.55
Market capitalisation	$640.7 million

TTM: trailing 12 months

Shorting Gossamer Bio shares

There are currently 11.2 million Gossamer Bio shares held short by investors – that's known as Gossamer Bio's "short interest". This figure is 1.2% up from 11.1 million last month.

There are a few different ways that this level of interest in shorting Gossamer Bio shares can be evaluated.

Gossamer Bio's "short interest ratio" (SIR)

Gossamer Bio's "short interest ratio" (SIR) is the quantity of Gossamer Bio shares currently shorted divided by the average quantity of Gossamer Bio shares traded daily (recently around 660163.71681416). Gossamer Bio's SIR currently stands at 16.95. In other words for every 100,000 Gossamer Bio shares traded daily on the market, roughly 16950 shares are currently held short.

However Gossamer Bio's short interest can also be evaluated against the total number of Gossamer Bio shares, or, against the total number of tradable Gossamer Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gossamer Bio's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Gossamer Bio shares in existence, roughly 150 shares are currently held short) or 0.1886% of the tradable shares (for every 100,000 tradable Gossamer Bio shares, roughly 189 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Gossamer Bio.

Find out more about how you can short Gossamer Bio stock.

Gossamer Bio share dividends

We're not expecting Gossamer Bio to pay a dividend over the next 12 months.

Gossamer Bio share price volatility

Over the last 12 months, Gossamer Bio's shares have ranged in value from as little as $7.92 up to $16.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gossamer Bio's is 1.2715. This would suggest that Gossamer Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Gossamer Bio overview

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.

Frequently asked questions

• What percentage of Gossamer Bio is owned by insiders or institutions?

  Currently 11.083% of Gossamer Bio shares are held by insiders and 81.825% by institutions.

• How many people work for Gossamer Bio?

  Latest data suggests 195 work at Gossamer Bio.

• When does the fiscal year end for Gossamer Bio?

  Gossamer Bio's fiscal year ends in December.

• Where is Gossamer Bio based?

  Gossamer Bio's address is: 3013 Science Park Road, San Diego, CA, United States, 92121

• What is Gossamer Bio's ISIN number?

  Gossamer Bio's international securities identification number is: US38341P1021

• What is Gossamer Bio's CUSIP number?

  Gossamer Bio's Committee on Uniform Securities Identification Procedures number is: 38341P102